Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00075049 · ClinicalTrials.gov registry record · Phase 1

Safety and Efficacy Study of RTS,S AS02A/AS01B Vaccine to Prevent Malaria

A Phase 1 study of Malaria, sponsored by U.S. Army Medical Research and Development Command.

Completed
Registry status
Phase 1
Development phase
104
Enrollment target
1
Study location

NCT00075049: Completed Phase 1 study of Malaria, sponsored by U.S. Army Medical Research and Development Command.

NCT00075049 is a Phase 1 study of Malaria that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 104 participants, below the 254-participant average among 27 other Malaria trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00075049, a Phase 1 study of Malaria, has completed, sponsored by U.S. Army Medical Research and Development Command.

COMPLETED
Registry status
Phase 1
Development phase
104 participants
Enrollment target
1
Study location

Study Summary

This is a double blinded study where 2 test vaccines will be evaluated to see if they protect persons who have never had malaria against malaria infection when bitten by mosquitoes.

Conditions Studied

Interventions

  • BIOLOGICAL RTS,S with AS02A/AS01B adjuvant

Study Locations (1)

Maryland

  • Walter Reed Army Institute of Research - Silver Spring

Trial Details

FieldValue
Enrollment Target 104 participants
Start Date 2003-12
Est. Completion 2006-01
Phase Phase 1

What the finished NCT00075049 record still lists

NCT00075049 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 254-participant average among 27 other Malaria trials with a reported enrollment target (59% lower).

The record links to 1 condition, with Malaria appearing as the primary indexed condition, and to 1 intervention - of which RTS,S with AS02A/AS01B adjuvant is the first listed.

NCT00075049 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00075049 about?

NCT00075049 is a clinical study titled "Safety and Efficacy Study of RTS,S AS02A/AS01B Vaccine to Prevent Malaria". This is a double blinded study where 2 test vaccines will be evaluated to see if they protect persons who have never had malaria against malaria infection when bitten by mosquitoes.

What is the current status of trial NCT00075049?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 104 participants. The study started on 2003-12. Estimated completion is 2006-01.

What conditions does trial NCT00075049 study?

This clinical trial studies the following conditions: Malaria.

What interventions are being tested in trial NCT00075049?

The interventions under investigation include: RTS,S with AS02A/AS01B adjuvant (BIOLOGICAL).

Who is sponsoring clinical trial NCT00075049?

This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00075049 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malaria

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00075049's enrollment target sits among peer trials

104 11th of 27 higher than 17 of 27 other Malaria trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Malaria trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03403686 · 104 participants

    Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)

  • NCT04228367 · 104 participants · NA

    JuggerStitch Post Market Clinical Follow-up Study

  • NCT04268849 · 104 participants · Phase 3

    Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient

  • NCT04390724 · 104 participants

    Optimizing Y90 Therapy for Radiation Lobectomy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00075049, the US trial registry maintained by the National Library of Medicine. NCT00075049 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.